Physical stability, biocompatibility and potential use of hybrid iron oxide-gold nanoparticles as drug carriers
Source abstract
Abstract
Hybrid nanoparticles (HNPs) such as iron oxide-gold nanoparticles are currently being exploited for their potential application in image-guided therapies. However, little investigation has been carried out into their physical or chemical stability and potential cytotoxicity in biological systems. Here, we determine the HNPs physical stability over 6 months and chemical stability in physiological conditions, and estimate the biological activity of uncoated and poly(ethylene glycol) coated nanoparticles on human pancreatic adenocarcinoma (BxPC-3) and differentiated human monocyte cells (U937). The potential of these HNPs to act as drug carrier vehicles was determined using the model drug 6-Thioguanine (6-TG). The data showed that the HNPs maintained their structural integrity both physically and chemically throughout the duration of the studies. In addition, negligible cytotoxicity or free radical production was observed in the cell lines tested. The 6-TG was successfully conjugated; with a ratio of 3:1:10 Fe:Au:6-TG (wt:wt:wt). After incubation with BxPC-3 cells, enhanced cellular uptake was reported with the 6-TG-conjugated HNPs compared with free drug along with a 10-fold decrease in IC50. This exciting data highlights the potential of HNPs for use in image-guided drug delivery.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoparticles: synthesis and applications · Gold and Silver Nanoparticles Synthesis and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (29)
Show source-provided references
1. Albanese A, Tang PS, Chan WCW (2012) The effect of nanoparticle size, shape and surface chemistry on biological systems. Annu Rev Biomed Eng 14:1–1610.1146/annurev-bioeng-071811-150124 ↗
2. Arruebo M, Fernández-Pacheco R, Ibarra R (2007) Magnetic nanoparticles for drug delivery. Nano Today 2:22–3210.1016/S1748-0132(07)70084-1 ↗
3. Barnett CM, Gueorguieva M, Lees MR, McGarvey DJ, Darton RJ, Hoskins C (2012) Effect of the hybrid composition on the physicochemical properties and morphology of iron oxide–gold nanoparticles. J Nanopart Res 14:117010.1007/s11051-012-1170-4 ↗
4. Buzea C, Pacheco B II, Robbie K (2007) Nanomaterials and nanoparticles: sources and toxicity. Biointerphases 2:MR17–MR17210.1116/1.2815690 ↗
5. Chatterjee S, Bandyopadhyay A, Sarkar K (2011) Effect of iron oxide and gold nanoparticles on bacterial growth leading towards biological application. J Nanobiotechnol 9:3410.1186/1477-3155-9-34 ↗
6. Dobson J (2006) Magnetic nanoparticles for drug delivery. Drug Dev Res 67:55–6010.1002/ddr.20067 ↗
7. Fadeel B, Garcia-Bennett AE (2010) Better safe than sorry: understanding the toxicological properties of inorganic nanoparticles manufactured for biomedical applications. Adv Drug Deliv Rev 62:362–37410.1016/j.addr.2009.11.008 ↗
8. Hoskins C, Ouaissi M, Lima SC, Cheng WP, Loureirio I, Mas E, Lombardo D, Cordeiro-sa-Silva A, Ouaissi A, Kong Thoo Lin P (2010) The study of in vitro and in vivo anticancer activity of a novel formulation incorporating PAA and BNIPDaoct against pancreatic cancer. Pharmaceut Res 27:2694–270310.1007/s11095-010-0268-6 ↗
9. Hoskins C, Min Y, Gueorguieva M, McDougall C, Volovick A, Prentice P, Wang Z, Melzer A, Cuschieri A, Wang L (2012a) Hybrid gold–iron oxide nanoparticles as a multifunctional platform for biomedical application. J Nanobiotechnol 10:2710.1186/1477-3155-10-27 ↗
10. Hoskins C, Wang L, Cuschieri A (2012b) The cytotoxicity of polycationic nanoparticles: common endpoint assays and alternative approaches for improved understanding of cellular response mechanism. J Nanobiotechnol 10:1510.1186/1477-3155-10-15 ↗
11. Hosoya H, Marunouchi T (1992) Differentiation and dedifferentiation of the human monocytic leukemia cell line, U937. Cell Strct Funct 17:263–26910.1247/csf.17.263 ↗
12. Ji X, Shao R, Elliott AM, Stafford J, Esparza-Coss E, Bankson JA, Liang G, Luo Z-P, Park K, Markert J-T, Li C (2007) Bifunctional gold nanoshells with a superparamagnetic iron oxide: silica core suitable for both MR Imaging and photothermal therapy. J Phys Chem C 111:6245–625110.1021/jp0702245 ↗
13. Jόzejczak A, Skumiel A (2011) Ultrasonic investigation of magnetic nanoparticles suspension with PEG biocompatible coating. J Magn Magn Mater 11:1509–151610.1016/j.jmmm.2011.01.009 ↗
14. Katsanos K, Tsianos EV (2010) Non-TPMT determiniants of azathioprine toxicity in imflammatory bowel disease. Ann Gastroenterol 23:95–101
15. Lancaster DL, Patel N, Lennard L, Lilleyman JS (2001) 6-Thioguanine in children with acute lymphoblastic leukaemia: influence of food on parent drug pharmacokinetics and 6-thioguanine nucleotide concentrations. BJCP 56:531–53910.1046/j.0306-5251.2001.01391.x ↗
16. Lu A-H, Salabas EL, Schüth F (2007) Magnetic nanoparticles: synthesis, protection, functionalization, and application. Angew Chem Int Ed 46:1222–124410.1002/anie.200602866 ↗
17. Lyer AK, Khaled G, Fang J, Maeda H (2006) Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 11:812–81810.1016/j.drudis.2006.07.005 ↗
18. Majumdar S, Tejo BA, Badawi AH, Moore D, Krise JP, Siahaan TJ (2009) Effect of modification of the physicochemical properties if ICAM-1-derived peptides on internalization and intracellular distribution in the human leukemic cell line HL-60. Mol Pharm 6:396–40610.1021/mp800120t ↗
19. Manson J, Kumar D, Meenan BJ, Dixon D (2011) Polyethylene glycol functionalized gold nanoparticles: the influence of capping density on stability in various media. Gold Bull 4:99–10510.1007/s13404-011-0015-8 ↗
20. Minotti G, Aust SD (1987) The requirement for Iron(III) in the initiation of lipid peroxidation by Iron(II) and hydrogen peroxide. J Biol Chem 262:1098–110410.1016/S0021-9258(19)75755-X ↗
21. Mishra S, Webster P, Davis ME (2004) PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. Eur J Cell Biol 83:97–11110.1078/0171-9335-00363 ↗
22. Peng J, Zou F, Liu L, Tang L, Yu L, Chen W, Liu H, Tang Jb Wu (2008) Preparation and characterization of PEG-PEI/Fe3O4 nano-magnetic fluid by co-precipitation method. Trans Nonferrous Met Soc China 18:393–39810.1016/S1003-6326(08)60069-2 ↗
23. Shubayev VI, Pisanic TR, Jun S (2009) Magnetic nanoparticles for theragnostics. Adv Drug Deliv Rev 61:467–47710.1016/j.addr.2009.03.007 ↗
24. Sorensen M, Autrup H, Moller P, Hertel O, Jensen SS, Vinzents P, Knudsen LE, Loft S (2003) Linking exposure to environmental pollutants with biological effects. Mutat Res 544:255–27110.1016/j.mrrev.2003.06.010 ↗
25. Sun C, Lee JSH, Zhang M (2008) Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev 60:1252–126510.1016/j.addr.2008.03.018 ↗
26. Vila A, Gill H, McCallion O, Alonso MJ (2004) Transport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating density. J Control Release 98:231–24410.1016/j.jconrel.2004.04.026 ↗
27. Wagstaff AJ, Brown SD, Holden MR, Craig GE, Plumb JA, Brown RE, Schreiter N, Chrzanowski W, Wheate NJ (2012) Cisplatin drug delivery using gold-coated iron oxide nanoparticles for enhanced tumour targeting with external magnetic fields. Inorg Chim Acta 393:328–33310.1016/j.ica.2012.05.012 ↗
28. Zaza G, Cheok M, Krynetskaia N, Thorn C, Stocco G, Hebert JM, McLeod H, Weinshilbourn RM, Relling MV, Evans WE, Klein TE, Altman RB (2010) Thiopurine pathway. Pharmacogenet Genomics 20:573–57410.1097/FPC.0b013e328334338f ↗
29. Zhu M-T, Feng W-Y, Wang B, Wang T-C, Gu Y-Q, Wang M, Wang Y, Ouyang H, Zhao Y-L, Chai Z-F (2008) Comparative study of pulmonary responses to nano- and submicron sized ferric oxide in rats. Toxicology 247:102–11110.1016/j.tox.2008.02.011 ↗